Last reviewed · How we verify
BPI-361175
At a glance
| Generic name | BPI-361175 |
|---|---|
| Sponsor | Betta Pharmaceuticals Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) (PHASE1, PHASE2)
- A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BPI-361175 CI brief — competitive landscape report
- BPI-361175 updates RSS · CI watch RSS
- Betta Pharmaceuticals Co., Ltd. portfolio CI